Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study

Next Previous
Trial Profile

Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Dec 2022 Results (n=10; From June 2021 to July 2022) assessing the safety and efficacy of anti-CD7 chimeric antigen receptor-T (CAR-T) therapies in teenagers and adult patients with relapsed/refractory (R/R) T cell malignancies, as well as differences between autologous and allogeneic CAR-T cells, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 25 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top